Literature DB >> 23307411

Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC.

R Khatib1, K Riederer, S Shemes, A C Musta, S Szpunar.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) vancomycin minimum inhibitory concentrations (V-MICs) are sometimes reported to be higher according to Etest versus broth microdilution (BMD). These observations are often interpreted as an Etest overestimation of the actual MIC. We measured V-MIC of 484 MRSA blood isolates using Etest, BMD, and a modified BMD (M-BMD) with incremental dilutions parallel to the Etest scale, correlated the results with population analysis profile-area under the curve (PAP-AUC). All MIC tests were done in parallel. The mean V-MIC was comparable (1.83 ± 0.44 [Etest], 1.88 ± 0.67 [BMD] and 1.75 ± 0.57 mg/L [M-BMD]; p = 0.9 [ANOVA]). The V-MICs/PAP-AUC correlation coefficient was 0.555 (Etest), 0.513 (BMD), and 0.586 (M-BMD). Etest MICs were equal (44.2 %), one dilution higher (21.9 %), two dilutions higher (2.5 %), one dilution lower (29.8 %), and two dilutions lower (1.6 %) than BMD MICs and were equal (61.5 %), one dilution higher (28.3 %), two dilutions higher (0.4 %), one dilution lower (9.5 %), and two dilutions lower (0.2 %) than M-BMD MICs. The mean PAP-AUC for Etest vs M-BMD among isolates with similar Etest/M-BMD MIC values was 0.25 ± 0.15 vs 0.35 ± 0.13 (p = 0.8), 0.46 ± 0.16 vs 0.50 ± 0.17 (p = 0.8), 0.64 ± 0.19 vs 0.67 ± 0.21 (p = 0.9), and 0.90 ± 0.31 vs 0.88 ± 0.25 (p = 1.0) for isolates with V-MIC of ≤ 1, 1.5, 2, and ≥ 3 mg/L respectively. These results suggest that Etest might not overestimate V-MIC in comparison to M-BMD or BMD; Etest and M-BMD tests depict comparable PAP-AUC and have a higher correlation with PAP-AUC than the conventional BMD, probably because of the more detailed results. Etest may be more suitable than conventional BMD for MIC outcome assessment because of the more detailed MICs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307411     DOI: 10.1007/s10096-012-1811-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used.

Authors:  V Prakash; J S Lewis; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

2.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

3.  Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Riad Khatib; Jinson Jose; Adina Musta; Mamta Sharma; Mohamad G Fakih; Leonard B Johnson; Kathleen Riederer; Stephen Shemes
Journal:  J Antimicrob Chemother       Date:  2011-04-26       Impact factor: 5.790

4.  Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer
Journal:  Int J Antimicrob Agents       Date:  2008-08-12       Impact factor: 5.283

5.  Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.

Authors:  Helio S Sader; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

6.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit.

Authors:  Thea Chua; Carol L Moore; Mary B Perri; Susan M Donabedian; William Masch; Dora Vager; Susan L Davis; Kaitlin Lulek; Benjamin Zimnicki; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

View more
  3 in total

1.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Multi-center prospective population pharmacokinetic study and the performance of web-based individual dose optimization application of intravenous vancomycin for adults in Hong Kong: A study protocol.

Authors:  Ka Ho Matthew Hui; Chung Yan Grace Lui; Ka Lun Alan Wu; Jason Chen; Yin Ting Cheung; Tai Ning Teddy Lam
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

3.  Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range.

Authors:  Cameron J Phillips; Nicholas A Wells; Marianne Martinello; Simon Smith; Richard J Woodman; David L Gordon
Journal:  Infect Drug Resist       Date:  2016-05-31       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.